NCT06370078 Effect of Early Administration of Albumin 20% Versus Crystalloid
| NCT ID | NCT06370078 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Egymedicalpedia |
| Condition | Septic Shock |
| Study Type | INTERVENTIONAL |
| Enrollment | 46 participants |
| Start Date | 2024-06-01 |
| Primary Completion | 2024-11-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 46 participants in total. It began in 2024-06-01 with a primary completion date of 2024-11-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Sepsis and septic shock are global health problems, leading to a high mortality rate. They are often associated with extremely low blood pressure and multiple organ dysfunctions, which are the main causes of death in critically ill patients. Fluid resuscitation is one of the most critical treatments for patients with sepsis and septic shock. An early administration of an appropriate fluid to patients is considered the most effective way to increase blood pressure, improve tissue perfusion, and save their lives. Crystalloid fluids are a subset of intravenous solutions composed of mineral salts and other small, water-soluble molecules, including normal, isotonic or hypertonic saline, and various buffered solutions.
Eligibility Criteria
Inclusion Criteria: * Presence of septic shock that meets all the following Criteria: Clinically possible, probable, or microbiologically confirmed infection according to the definitions of the International-Sepsis- Forums (ISF), Despite adequate volume therapy, vasopressors are required to maintain mean arterial pressure (MAP) ≥ 65 mmHg for at least 1 hour, Serum lactate concentration \> 2 mmol/l (18 mg/dl) despite adequate volume therapy. * Onset of septic shock less than 24 h prior to study inclusion. * Women of childbearing age: negative pregnancy test Exclusion Criteria: * Moribund conditions * End of life decisions * Previous participation to this trial or any other interventional clinical trial * Known hypersensitivity to albumin or any component of the trial drug * Clinical conditions, where albumin administration may be unfavourable * Breast feeding
Contact & Investigator
Mohamed Ahmed Mohamed, Professor
STUDY CHAIR
ICU department , Faculty of Medicine, Assuit University
Frequently Asked Questions
Who can join the NCT06370078 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Septic Shock. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06370078 currently recruiting?
Yes, NCT06370078 is actively recruiting participants. Contact the research team at Ahmedel3oksh@gmail.com for enrollment information.
Where is the NCT06370078 trial being conducted?
This trial is being conducted at Asyut, Egypt.
Who is sponsoring the NCT06370078 clinical trial?
NCT06370078 is sponsored by Egymedicalpedia. The principal investigator is Mohamed Ahmed Mohamed, Professor at ICU department , Faculty of Medicine, Assuit University. The trial plans to enroll 46 participants.